Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor.
作者信息
Kim J H, Lim M C
机构信息
Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea.
Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea; Cancer Control and Policy, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea; Rare & Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
出版信息
ESMO Open. 2025 Jun;10(6):105288. doi: 10.1016/j.esmoop.2025.105288. Epub 2025 May 27.
Abstract
摘要
相似文献
1
Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：BRCT结构域对PARP抑制剂反应的种族差异
ESMO Open. 2025 Jun;10(6):105288. doi: 10.1016/j.esmoop.2025.105288. Epub 2025 May 27.
2
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.对关于“根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都相同：功能背景和突变类型作为PARP抑制剂反应的共同决定因素”的信件的回复
ESMO Open. 2025 Jun;10(6):105299. doi: 10.1016/j.esmoop.2025.105299. Epub 2025 May 29.
3
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.对关于“根据BRCA1/2突变类型和位点，PARP抑制剂维持治疗对新诊断卵巢癌的获益：一项多中心真实世界研究”信件的回复
ESMO Open. 2025 Jun;10(6):105289. doi: 10.1016/j.esmoop.2025.105289. Epub 2025 May 29.
4
Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都是等同的：功能背景和突变类型作为PARP抑制剂的共同决定因素
ESMO Open. 2025 Jun;10(6):105298. doi: 10.1016/j.esmoop.2025.105298. Epub 2025 May 29.
5
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究
ESMO Open. 2025 Apr;10(4):104533. doi: 10.1016/j.esmoop.2025.104533. Epub 2025 Apr 1.
6
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂作为新诊断卵巢癌女性的维持治疗：系统评价和荟萃分析。
Arch Gynecol Obstet. 2021 Aug;304(2):285-296. doi: 10.1007/s00404-021-06070-2. Epub 2021 May 21.
7
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚（ADP-核糖）聚合酶（PARP）抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
8
The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer.BRCA突变位置与PARP抑制剂作为晚期上皮性卵巢癌一线维持治疗疗效之间的关联
Cancers (Basel). 2025 Feb 23;17(5):756. doi: 10.3390/cancers17050756.
9
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.对携带BRCA1或BRCA2基因突变的女性进行降低风险的双侧输卵管卵巢切除术。
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
10
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study.与多原发性肿瘤高风险相关的BRCA功能域及与奥拉帕利相关的结构域敏感性：普罗米修斯研究
ESMO Open. 2025 Feb;10(2):104076. doi: 10.1016/j.esmoop.2024.104076. Epub 2025 Jan 22.
本文引用的文献
1
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.对关于“根据BRCA1/2突变类型和位点，PARP抑制剂维持治疗对新诊断卵巢癌的获益：一项多中心真实世界研究”信件的回复
ESMO Open. 2025 Jun;10(6):105289. doi: 10.1016/j.esmoop.2025.105289. Epub 2025 May 29.
2
The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer.BRCA突变位置与PARP抑制剂作为晚期上皮性卵巢癌一线维持治疗疗效之间的关联
Cancers (Basel). 2025 Feb 23;17(5):756. doi: 10.3390/cancers17050756.
3
Reversion of pathogenic L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer.致病性L1780P突变的逆转赋予乳腺癌对PARP和ATM抑制剂的抗性。
iScience. 2024 Jul 6;27(8):110469. doi: 10.1016/j.isci.2024.110469. eCollection 2024 Aug 16.
4
Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea.基于韩国的临床证据，BRCA1基因c.5339T>C（p.L1780P）变异的分类从“意义未明”变更为“可能致病”。
Breast. 2017 Jun;33:109-116. doi: 10.1016/j.breast.2017.03.006. Epub 2017 Mar 30.
5
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.序列变异解读的标准与指南：美国医学遗传学与基因组学学会和分子病理学协会的联合共识推荐
Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.
Zotero 插件